Alnylam Pharmaceuticals
ALNY
#378
Rank
โ‚น5.437 T
Marketcap
โ‚น41,156
Share price
-1.55%
Change (1 day)
89.65%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Revenue for Alnylam Pharmaceuticals (ALNY)

Revenue in 2025 (TTM): โ‚น278.95 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current revenue (TTM ) is โ‚น288.38 Billion. In 2024 the company made a revenue of โ‚น192.86 Billion an increase over the revenue in the year 2023 that were of โ‚น152.20 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Alnylam Pharmaceuticals from 2004 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) โ‚น278.95 B44.63%
2024 โ‚น192.86 B26.72%
2023 โ‚น152.20 B77.3%
2022 โ‚น85.84 B36.61%
2021 โ‚น62.84 B74.34%
2020 โ‚น36.04 B130.01%
2019 โ‚น15.67 B199.19%
2018 โ‚น5.23 B-8.77%
2017 โ‚น5.74 B79.14%
2016 โ‚น3.20 B17.34%
2015 โ‚น2.73 B-14.77%
2014 โ‚น3.20 B9.97%
2013 โ‚น2.91 B-20.24%
2012 โ‚น3.65 B-16.55%
2011 โ‚น4.37 B-2.34%
2010 โ‚น4.48 B-3.9%
2009 โ‚น4.66 B0.92%
2008 โ‚น4.62 B131.4%
2007 โ‚น1.99 B67.47%
2006 โ‚น1.19 B363.7%
2005 โ‚น0.25 B38.83%
2004 โ‚น0.18 B

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Arrowhead Pharmaceuticals
ARWR
โ‚น51.47 B-82.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
โ‚น1.279 T 343.85%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
โ‚น216.83 B-24.81%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
โ‚น57.68 B-80.00%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
โ‚น5.064 T 1,656.10%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
โ‚น4.269 T 1,380.50%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
โ‚น1.507 T 422.61%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel